ProPharma is excited to welcome Kevin van Dooren as Vice President, Health Economics and Outcomes Research (HEOR) and Market Access, to our Regulatory Sciences team. The addition of Kevin marks a significant step forward in our commitment to delivering fully integrated regulatory and market access solutions to clients navigating the evolving European landscape.
Kevin brings more than 15 years of experience in health economics, market access, reimbursement, and HTA strategy, with a strong track record of enabling access for innovative therapies across pharmaceuticals, MedTech, and digital health. His expertise spans global and affiliate roles, providing a unique ability to connect strategic market access planning with practical, in-market execution.
As the EU HTA Regulation comes into force, early alignment of regulatory and HTA strategies is becoming critical for successful product development and access. Kevin brings deep experience in pan-European HTA strategy, including readiness for Joint Clinical Assessments (JCA) and Joint Scientific Consultations (JSC), as well as integrated evidence planning across centralized regulatory and national access pathways.
In his role at ProPharma, Kevin will lead and expand our HEOR and market access capabilities, supporting clients with:
JCA and JSC strategy and execution under HTAR
Integrated evidence generation planning aligned with regulatory and payer expectations
Development of value dossiers, economic models, and real-world evidence strategies
Local pricing and reimbursement strategies across Europe
Kevin’s appointment further strengthens ProPharma’s ability to provide seamless, end-to-end support across the entire product lifecycle, from early development strategy through to Marketing Authorisation Application (MAA) and market access.
By combining regulatory expertise with HEOR and market access leadership, ProPharma is uniquely positioned to help clients navigate:
The increasing interdependence of regulatory and HTA requirements in Europe
Parallel evidence expectations for EMA approval and HTA decision-making
The need for early, coordinated planning to support both clinical development and value demonstration
This integrated approach is particularly critical for advanced therapeutic medicinal products (ATMPs), oncology therapies, and emerging orphan products, where robust and aligned clinical and economic evidence is essential to demonstrate value to both regulators and payers.
Kevin has led large international teams and worked closely with HTA bodies, payers, and policy stakeholders to shape reimbursement pathways for innovative products. His leadership will further enhance ProPharma’s ability to:
Deliver holistic development strategies that anticipate HTA requirements from the outset
Support efficient, coordinated submissions across regulatory and access pathways
Maximize the likelihood of timely patient access in Europe and beyond
With the addition of Kevin to our leadership team, ProPharma continues to invest in capabilities that reflect the evolving needs of our clients. As HTAR reshapes the European landscape, we are committed to providing forward-looking, integrated solutions that enable successful development, approval, and access for the next generation of therapies.